Ketamine for Treatment-Resistant Depression is organized by The American Psychiatric Association (APA).

Start Date: Jan 01, 2018
End Date: Dec 31, 2020

Accreditation:
This Online CME Course has been recommended for a maximum of 0.5 AMA PRA Category 1 Credits.

Course Description:
This presentation explains, in detail, the results of randomized trials of intravenous or intranasal ketamine for treatment-resistant unipolar and bipolar major depression, emphasizing the methodological limitations of the most significant studies and limitations of study findings for long-term ketamine administration. The presenter is a clinician accustomed to the utilization of intravenous ketamine in acute settings at a larger academic medical center.

Course Objectives
• Explain the principal findings from the most important studies of the effectiveness and safety of low-dose ketamine for the acute management of treatment-resistant unipolar or bipolar major depression.
• Describe the principal short- and long-term safety and tolerability concerns regarding the use of low-dose ketamine for the management of treatment-resistant unipolar or bipolar major depression.
• Review the techniques applied at Mayo Clinic and clinical programming steps that have been undertaken in order to develop a ketamine infusion therapy service.

This course is currently offered as a free member benefit through the Course of the Month program. Promotional pricing valid from January 1-31, 2018.

• CME : 0.5

Psychiatrists, Residents/Fellows

Number of Health Care Professionals Registered: 16 Number